New Maverex cost-consequence analysis of triple-chamber-bag parenteral nutrition in preterm neonates

 

In Cost-Consequences Analysis of Increased Utilization of Triple-Chamber-Bag Parenteral Nutrition in Preterm Neonates in Seven European Countries, alongside our partners at Baxter Healthcare, we assessed national-level impacts of a 10-percentage point increase in use of industry-prepared three-chamber bags (3CBs) on clinical outcomes, healthcare resources, and hospital budgets across seven countries: Belgium, France, Germany, Italy, Portugal, Spain, and the UK.

This study estimated the impact on compounding error harm and bloodstream infection rates, staff time, and annual hospital budget, finding that even a small increase in the use of 3CBs in preterm neonates could substantially improve neonatal clinical outcomes and provide notable resource and cost savings to hospitals.

To read the full manuscript (free to access) click here, or to talk to us about your research needs or challenges, email enquiries@maverex.com.